Cell Source Inc (CLCS) Return on Equity ROE from the first quarter 2025 to first quarter 2024 and annually, average high and low, overall ranking from Mar 31 2025 to Mar 31 2024 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Cell Source Inc   (CLCS)

Cell Source Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Cell Source Inc in the first quarter 2025?
Due to the lack of equity, it was not possible to calculate Cell Source Inc 's return on equity (ROE) in its first quarter 2025

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Mar 31 2025)
I. Quarter		 (Dec 31 2024)
IV. Quarter		 (Sep 30 2024)
III. Quarter		 (Jun 30 2024)
II. Quarter		 (Mar 31 2024)
I. Quarter
Y / Y Equity Change - - - - -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -5 -5 -5 -5 -5
Return On Equity (TTM) - - - - -
CLCS's Total Ranking # # # # #
Equity (TTM) in Millions -20 -19 -19 -17 -17
Seq. Equity Change - - - - -
Seq. Net Income Change - - - - -

Back to CLCS Management Effectiveness >> CLCS's 5 Years Annual ROE >> Compare CLCS ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry #
Sector #
Overall #

Return On Equity Statistics
High Average Low
0 %
0 %
0 %
 





CLCS Annual Return On Equity (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021		 (Dec 31 2020)
2020
Total Equity in Millions -19 -16 -13 -10 -8
Y / Y Equity Change - - - - -
Net Income in Millions -5 -5 -5 -5 -5
Y / Y Net Income Change - - - - -
Return On Equity - - - - -

Back to CLCS Management Effectiveness >> CLCS's 5 Years Annual ROE >> Compare CLCS ROE to its Competitors




More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
CLCS's' Return on Equity at Yahoo Finance
CLCS's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for CLCS's Competitors
Subscribers only: Roe for Cell Source Inc 's Suppliers
Subscribers only: Return On Equity for CLCS's Customers




Companies with similar Return On Equity at Mar 31 2025, within Healthcare Sector ROE
Exelixis Inc   67.57 %
Dariohealth Corp   65.81 %
Pharmacyte Biotech Inc   62.23 %
Idexx Laboratories Inc  57.35 %
Medpace Holdings Inc   54.36 %
Agios Pharmaceuticals Inc   50.31 %
Zoetis Inc   50.22 %
Puma Biotechnology Inc   49.30 %
Edwards Lifesciences Corporation  44.69 %
Sbc Medical Group Holdings Incorporated  44.32 %
Tenet Healthcare Corp  42.42 %
Agilent Technologies inc   41.87 %
Waters Corporation  38.48 %
Merck and Co Inc   38.15 %
Hims and Hers Health Inc   35.97 %
Acadia Pharmaceuticals Inc   35.32 %
Insulet Corporation  34.53 %
Lifevantage Corp  32.20 %
Bristol myers Squibb Company  31.93 %
Gilead Sciences Inc   31.85 %
Nutriband Inc   30.78 %
Abbott Laboratories  30.59 %
Concentra Group Holdings Parent Inc   30.50 %
Johnson and Johnson  29.95 %
X4 Pharmaceuticals Inc  29.32 %
Pro dex Inc   29.30 %
Prestige Consumer Healthcare Inc   28.91 %
Biomx Inc  28.29 %
Catalyst Pharmaceuticals Inc   28.28 %
Ge Healthcare Technologies Inc   26.61 %

Date modified: 2026-09-08T15:11:41+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.